retatrutide trial results news today This is exciting. 👀 The TRIUMPH-4 for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far Retatrutide approval: FDA status, clinical

PMCID: PMC10301284

This could open entirely new treatment categories and support the next phase of market expansion. Implications for Other Industries Food companies may be among the most exposed to increased GLP-1 adoption, as patients typically reduce calorie intake while on these therapies

Even minor structural changes from improper storage can reduce or eliminate binding affinity at one or more receptor sites, which directly impacts the compound effectiveness for fat loss , appetite suppression, and metabolic regulation

Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function

Glutathione-mediated thermomorphogenesis and heat stress responses in Arabidopsis thaliana